🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

676 results for “Solid” Clear

  1. Trastuzumab deruxtecan

    AstraZeneca

    Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

    phase 2 small molecule active

    1 trial
  2. Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial
  3. Tumor Intiltrating Lymphocytes (TIL) – VHIO, Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG, Melanoma Tumor Intiltrating Lymphocytes (TIL) – NKI, Fludarabine - PCH 25 mg/ml, concentraat voor oplossing voor intraveneuze infusie of injectie, ANV419, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Genoxal 1.000 mg polvo para solución inyectable y para perfusión, PROLEUKIN, 18x106 UI polvo para solución inyectable o para perfusión, PROLEUKIN®

    The George Institute

    Advanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

    phase 2 small molecule active

    1 trial
  4. VB10.NEO

    Nektar Therapeutics UK Limited

    Locally Advanced or Metastatic Solid Tumours

    phase 2 mab completed

    1 trial
  5. VESANOID 10 mg, capsule molle

    The George Institute

    Oligometastatic solid cancer

    phase 2 small molecule active

    1 trial
  6. Valemetostat Tosylate, Valemetostat Tosylate

    The George Institute

    Adult patients with histologically/cytologically confirmed progressive metastatic or recurrent solid tumor, who have selected chromatin remodeling deficiency in at least one of the following genes: SMARCB1, SMARCA4, SMARCA2, SMARCC1, SMARCC2, ARID1A, ARID1B, PBRM1, BAP1and other SWI/SNF sub-units; or molecularly (Wildtype) and phenotypically-selected Clear cell endometrial or ovarian carcinoma cancers.

    phase 2 small molecule active

    1 trial
  7. WTX-330

    Werewolf Therapeutics

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    2 trials
  8. XTX202

    Xilio Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule completed

    1 trial
  9. XTX301

    Xilio Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial
  10. YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, KITE-363

    Lacuna Pharma Pty Ltd

    Solid and Hematological Malignancies

    phase 2 small molecule active

    1 trial
  11. Zilovertamab vedotin

    Merck Sharp and Dohme

    Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

    phase 2 small molecule active

    1 trial
  12. Zirabev 25 mg/ml concentrate for solution for infusion, SAR445877, Erbitux 5 mg/mL solution for infusion, Zirabev 25 mg/ml concentrate for solution for infusion

    Sanofi-aventis Healthcare Pty Ltd

    Solid tumor

    phase 2 small molecule active

    1 trial
  13. [177Lu]-NeoB solution for infusion, AAA503

    Advanced Accelerator Applications

    Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake.

    phase 2 small molecule active

    1 trial
  14. anti-IL8 mAb, Ipilimumab, anti-IL8 mAb, 5% dextrose solution for injection, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, 0.9% sodium chloride solution for injection

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors

    phase 2 small molecule active

    1 trial
  15. cemiplimab (monotherapy)

    Regeneron UK Limited

    Relapsed Solid Tumor

    phase 2 small molecule terminated

    1 trial
  16. cetrelimab, JNJ-63723283

    Janssen-Cilag International N.V.

    Advanced Stage Solid Tumors

    phase 2 small molecule active

    1 trial
  17. dabrafenib

    GlaxoSmithKline

    Solid Tumours

    phase 2 small molecule completed

    1 trial
  18. docetaxel+CDDP

    Solid Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial
  19. farletuzumab ecteribulin, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules

    Eisai Co.,

    Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC).

    phase 2 small molecule active

    1 trial
  20. genexolPM + cisplatin

    Solid Biosciences

    Locally Advanced Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial
  21. indibulin

    Alaunos Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    2 trials
  22. ipatasertib

    United Therapeutics Europe Ltd

    Solid Tumor

    phase 2 small molecule active

    1 trial
  23. ivosidenib and nivolumab

    Agios Netherlands B.V.

    Advanced Solid Tumor

    phase 2 small molecule completed

    1 trial
  24. rezatapopt

    PMV Pharmaceuticals

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources